-
Je něco špatně v tomto záznamu ?
State of the art management practices for liver glycogen storage disorders: Results from an international survey among metabolic centres
SC. Grünert, TGJ. Derks, A. Rossi, GSD Collaboration group
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- MeSH
- glykogenóza * terapie diagnóza MeSH
- játra metabolismus patologie MeSH
- lidé MeSH
- management nemoci MeSH
- nemoci jater * terapie diagnóza MeSH
- průzkumy a dotazníky MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Liver glycogen storage disorders (GSDs) are rare inherited disorders of carbohydrate metabolism that are clinically characterized by hepatomegaly and fasting intolerance. This group of disorders comprises GSD Ia and Ib as well as the so-called ketotic GSDs including GSD III, VI, IX, XI and 0a. Although clinical practice guidelines exist for most GSD subtypes, diagnostics, treatment and monitoring differ significantly among metabolic centres. The aim of this study was to gain insight into current clinical practice for liver GSDs. METHODS: An international web-based survey was performed among health care professionals involved in the care of individuals with liver GSDs. RESULTS: Sixty-seven respondents from 28 different countries caring for approximately 2650 liver GSD patients completed the survey. While the diagnostic approach was generally consistent, significant differences among metabolic centres are still observed with respect to monitoring parameters and treatment approaches. Reasons for these differences are local availability of management tools and treatment options, the rarity of the different GSD subtypes, the experiences of health care professionals, and the existence of extreme phenotypes. CONCLUSION: The development of a standard set of outcomes for patients with liver GSDs is warranted as a reference for both daily care and the evaluation of safety and efficacy of future therapies. For various parameters that serve as valuable outcome measures, tools and target values should be better defined.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25015176
- 003
- CZ-PrNML
- 005
- 20250731090811.0
- 007
- ta
- 008
- 250708s2025 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ymgme.2025.109129 $2 doi
- 035 __
- $a (PubMed)40435569
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Grünert, Sarah C $u Department of General Pediatrics, Adolescent Medicine and Neonatology, Medical Centre - University of Freiburg, Faculty of Medicine, Freiburg, Germany. Electronic address: sarah.gruenert@uniklinik-freiburg.de
- 245 10
- $a State of the art management practices for liver glycogen storage disorders: Results from an international survey among metabolic centres / $c SC. Grünert, TGJ. Derks, A. Rossi, GSD Collaboration group
- 520 9_
- $a BACKGROUND: Liver glycogen storage disorders (GSDs) are rare inherited disorders of carbohydrate metabolism that are clinically characterized by hepatomegaly and fasting intolerance. This group of disorders comprises GSD Ia and Ib as well as the so-called ketotic GSDs including GSD III, VI, IX, XI and 0a. Although clinical practice guidelines exist for most GSD subtypes, diagnostics, treatment and monitoring differ significantly among metabolic centres. The aim of this study was to gain insight into current clinical practice for liver GSDs. METHODS: An international web-based survey was performed among health care professionals involved in the care of individuals with liver GSDs. RESULTS: Sixty-seven respondents from 28 different countries caring for approximately 2650 liver GSD patients completed the survey. While the diagnostic approach was generally consistent, significant differences among metabolic centres are still observed with respect to monitoring parameters and treatment approaches. Reasons for these differences are local availability of management tools and treatment options, the rarity of the different GSD subtypes, the experiences of health care professionals, and the existence of extreme phenotypes. CONCLUSION: The development of a standard set of outcomes for patients with liver GSDs is warranted as a reference for both daily care and the evaluation of safety and efficacy of future therapies. For various parameters that serve as valuable outcome measures, tools and target values should be better defined.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a glykogenóza $x terapie $x diagnóza $7 D006008
- 650 _2
- $a játra $x metabolismus $x patologie $7 D008099
- 650 _2
- $a průzkumy a dotazníky $7 D011795
- 650 12
- $a nemoci jater $x terapie $x diagnóza $7 D008107
- 650 _2
- $a management nemoci $7 D019468
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Derks, Terry G J $u Section of Metabolic Diseases, Beatrix Children's Hospital, University Medical Center of Groningen, University of Groningen, Groningen, the Netherlands; UMCG Center of Expertise for Carbohydrate, Fatty Acid Oxidation and Ketone Bodies Disorders, University Medical Center Groningen, Groningen, the Netherlands
- 700 1_
- $a Rossi, Alessandro $u Department of Translational Medicine, Section of Pediatrics, University of Naples "Federico II", Naples, Italy
- 710 2_
- $a GSD Collaboration group
- 773 0_
- $w MED00006573 $t Molecular genetics and metabolism $x 1096-7206 $g Roč. 145, č. 3 (2025), s. 109129
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40435569 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731090806 $b ABA008
- 999 __
- $a ok $b bmc $g 2366183 $s 1252301
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 145 $c 3 $d 109129 $e 20250506 $i 1096-7206 $m Molecular genetics and metabolism $n Mol Genet Metab $x MED00006573
- LZP __
- $a Pubmed-20250708
